Diligence memo · auto-generated · as of July 2, 2026
Cage Bio, Inc.
Cage Bio, Inc. looks over-valued against its niche peers and is at-risk on financing cadence.
Businessfiled
Cage Bio, Inc. operates in Pharmaceuticals, based in SAN CARLOS.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Cage Bio, Inc. has raised $29M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $11M on 2024-04-15.
Most recent recorded round closed around 2024-04-15.
Valuation (modeled)modeled
Provath models Cage Bio, Inc. at approximately $62M (range $13M–$141M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 1.91× the median modeled value of Series A Pharmaceuticals companies in 2022–2024 (64 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 14 months.
Last raise 2.2 yr ago; this sector typically re-raises about every 13 months.
Past due for a raise versus sector cadence — watch for distress or a bridge.
The last round stepped up 2.3× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 72% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 47% of those peers.
Closest niche peers: Hallux, Inc., Enalare Therapeutics Inc., Silver Creek Pharmaceuticals, Inc., NQ PE Project Stingray Parent, L.P., Acta Pharmaceuticals, Inc..
Peoplefiled
4 named people on file across officers, directors and signatories.
Risks & flagsmixed
Overdue for a raise versus sector norm — distress or bridge risk.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.